Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Poster on systems pharmacology of the cholesterol biosynthesis pathway


Published on

A systems pharmacology study of the cholesterol biosynthesis pathway

Poster presented at the Pharmacology 2017 conference, London, December 2017

Published in: Science
  • Be the first to comment

  • Be the first to like this

Poster on systems pharmacology of the cholesterol biosynthesis pathway

  1. 1. 3. Results (I) 2. Pathway production 6. References 1 Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK. 2 Northern Ireland Centre for Stratified Medicine, University of Ulster, C-Tric, Derry, UK (current addresses for HEB and CPM are given in reference [2]) @GuidetoPHARM A systems pharmacology study of the cholesterol biosynthesis pathway Supported by: We especially thank all contributors, collaborators and NC-IUPHAR members 1. Introduction Information on drugs, lead compounds and their pharmacological effects is expanding in online resources, including the IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) [1]. This means that for key pathways and modules there is an expansion in the number of data-supported druggable targets captured in databases. As this catalogue of molecular interactions and our understanding of biological systems expands, it will be advantageous to integrate these resources in order to devise new potential therapies. Drug combinations present an opportunity for therapy development that can target pathways more precisely than perturbing entire networks. Systems pharmacology will also impact genomic medicine, including personalisation of treatments and stratification of patient groups. Thus, as our understanding increases, we have opportunities to predict, model, quantify and test combinations that may have advantages over conventional single-drug therapies. This work explores the feasibility of such systems pharmacology approaches with an analysis of the mevalonate branch of the cholesterol biosynthesis pathway. This poster is a summary of a detailed paper published in Sept 2017 that also includes extensive supplementary data [2]. Updates of our extensive curation of the pathway are now in GtoPdb as below. Figure 1. These snap shots are taken from the pathway display in: The summary links specify the protein properties and detailed pages display kinetic parameters along with substrates and inhibitors for the enzymes as ligand entries. Figure 1. Examples of various kinase database tables 1. Harding SD, et al. (2018) The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new Guide to IMMUNOPHARMACOLOGY. Nucl. Acids Res. 46 (Database Issue). doi: 10.1093/nar/gkx1121. 2. Benson, HE et al, (2017) Is systems pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway. Br. J. Pharmacol. Sep 14. doi: 10.1111/bph.14037. [Epub ahead of print] 3. Mazein A et al. (2013) A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway. Biochem Pharmacol. 86(1):56-66. doi: 10.1016/j.bcp.2013.03.021 . GtoPdb is an ELIXIR UK node resource 4. Model of the mevalonate arm of the cholesterol pathway We produced a model of the mevalonate arm of the cholesterol biosynthesis pathway in Systems Biology Graphical Notation (SBGN) for the metabolic steps from acetyl-CoA and acetoacetyl-CoA consumption to squalene and geranylgeranyl diphosphate production. This comprises 12 steps, 10 enzymes and 14 metabolites. Figure 2. The full enzyme names for this pathway diagram are in Fig.1 We used the model to calculate steady-state flux profiles without inhibitors and then tested the affects of drug combinations on fluxes via computational optimization. We determined a combination of five inhibitors showed the desired suppression squalene while maintaining normal geranyl diphosphate levels (full details are available in [2]) Christopher Southan1, Helen E. Benson1, Steven Watterson2, Joanna L. Sharman1, Chido P. Mpamhanga1 and Andrew Parton2 5. Conclusions Our initial attempts to build a systems pharmacology model of the mevalonate arm of the cholesterol biosynthesis pathway revealed gaps and inconsistencies in the data that prevented us from achieving a high level of confidence. In particular, we found the lack of comprehensive and systematic parameterizations, experimental variation, ambiguity in structural detail and inappropriate and inaccurate reporting from the primary literature to be obstacles. That this should be the case for a pathway of such high biomedical and commercial significance was unexpected. For this reason, our best current parameterization represents a patchwork of values taken from multiple species and experimental configurations. Nonetheless, by completing gaps in our knowledge with representative values, we were able to demonstrate subtle reprogramming of pathway dynamics that may contribute significantly to drug development. We propose that these obstacles can be reduced through the adoption of standards and quality control. Although we have focused on the mevalonate arm of cholesterol biosynthesis, this approach could be applied to any pathway of interest for which targets, ligands and kinetic parameters are known. Note also that GtoPdb expands the capture of ligand-to- target relationships every release. However, extending modelling opportunities more generally needs both the computational biology and the pharmacology communities to reduce barriers to progress. The model from this work and our previous study [3] is available from (ID 1506220000) and can freely be used and adapted. We combined the interrogation of multiple databases and cross-checking primary literature to establish the enzymes involved in the pathway, the reactions they catalyse, subcellular localization, species in which they were identified, substrate, kinetic parameters and inhibitors. This uncovered some inconsistences and ambiguities in database entries that we had to resolve against data specified in the papers. We combined ordinary differential equation (ODE) kinetic models, the pathway parameters and the inhibitor parameters to create a model describing the dynamics of the mevalonate pathway. This incorporated Michaelis–Menten kinetics to describe each step, except the interactions consuming isopentenyl diphosphate and producing geranylgeranyl diphosphate and pre-squalene diphosphate. These steps were described using mass action kinetics in order to simplify the process of calculating the steady state of the model and hence the steady state behaviour of the pathway. We then sought to identify the drug combination that would best suppress the production of squalene as a precursor for cholesterol, but would also maintain production of geranylgeranyl-diphosphate at the same levels as in the absence of any inhibitors, thereby eliminating a significant side-effect of treatment. After establishing the steady-state activity of the pathway in the absence of inhibitors, we then we used computational optimization to identify a drug combination that, at steady state, minimized squalene production, but left geranylgeranyl diphosphate production the same as in the absence of inhibitors.